Stock RLMD RELMADA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Relmada Therapeutics, Inc.

Equities

RLMD

US75955J4022

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
3.83 USD +3.51% Intraday chart for Relmada Therapeutics, Inc. -4.25% -7.49%
Mar. 19 Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024
Mar. 19 Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
AQ
Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024
Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
PR
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
PR
Relmada Says Chief Medical Officer Leaving; Names Senior Clinical Development Advisor
MT
Relmada Therapeutics Provides Corporate Update
PR
Relmada Therapeutics, Inc. Announces Resignation of Cedric O?Gorman as Chief Medical Officer
CI
Transcript : Relmada Therapeutics, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Relmada Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023
PR
Relmada Therapeutics Reports Positive Preclinical Data on its Psilocybin Program to Treat Liver Disease
MT
Relmada Therapeutics to Present New Preclinical Data on Its Psilocybin Program At AASLD the Liver Meeting 2023
CI
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS, Neuro Summit
AQ
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology Congress
AQ
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
PR
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress
PR
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
PR
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from S&P Global BMI Index
CI
Relmada Therapeutics, Inc. Announces Eric Schmidt to Resign from the Board, Chairman of the Audit Committee of the Board and as A Member of the Corporate Governance and Nominating Committee of the Board
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RLMD Stock
  4. News Relmada Therapeutics, Inc.